ETCEMBLY
THE CHALLENGE
Innovative techbio startup Etcembly wanted to come out of stealth mode with a splash, raising awareness of the company and their unique EMLy AI immune engineering platform ahead of their next raise with a compelling story that set them apart from the crowd and showcased their cutting-edge science.
OUR APPROACH
We knew we needed a compelling story to catch attention, so we developed a media campaign around the announcement of their lead programme ETC-101 – the world’s first generative AI-designed T cell receptor therapeutic.
We produced a press release explaining the story and the science behind it, along with a Q&A about the company. We then pitched it to our curated media through personal journalist outreach, along with newswire placement and a LinkedIn campaign.
We were delighted to get high quality coverage in a range of outlets, from specialist life science media to business publications including Forbes and Inc, earning us a place on the 2024 One Nucleus Genesis BioNewsRound award shortlist.
We continued to work with Etcembly for more than two years to establish them as a leader in the AI-driven immunotherapy space.
This included further press releases and media outreach, planning and creating thought leadership and explainer articles for their blog and external outlets (for example, Drug Target Review), regular posting on LinkedIn, support with BD assets such as one-pagers and animations, presentation skills training, and ongoing strategic comms advice and support as the company developed.
KEY RESULTS
High quality coverage in a number of relevant target outlets
Generated awareness among biopharma and general media for future stories
1000% increase in reactions on LinkedIn
Shortlisted for One Nucleus Genesis 2024 BioNewsRound award
WHAT THEY SAID
“FCTM did a great job of bringing the story of our important milestone to life, making it easy to understand and engaging. The positive feedback from our board and heightened media coverage and interest we received underline this. They continued to be an excellent team to work with, and always offered interesting and different perspectives on how to get the message out – experts in their field!”
FIND OUT ABOUT SOME OF OUR OTHER WORK
Nine days to get noticed
Sensible Biotechnologies came to us for help announcing they had secured support from NVIDIA for their innovative AI-powered cell-based mRNA manufacturing platform. Excitingly, they had secured a mention in the AI giant’s blog featuring Europe’s leading life science...
Helping an ambitious biotech startup stand out from the crowd
Oxford-based techbio startup Scripta Therapeutics had closed a $12 million seed funding round to build their innovative drug discovery platform. It was time to come out of stealth mode and grab the world’s attention with an eye-catching brand, website, and PR...
How we translated complex science into a high-value lead generation asset
Particology needed to grow their new business pipeline, and were looking for help communicating their highly technical science in a way that would help them stand out and showcase their expertise to their target audiences. They wanted a clear, professional marketing...
A bit of everything: Flexible, wide-ranging comms & marketing support for a growing life science company
Depixus first approached us in 2022 looking for help producing marketing materials that clearly articulated the technology and benefits of their highly innovative large-scale magnetic force spectroscopy platform for measuring individual biomolecular interactions. It...
Flexible, high-quality science content support for a busy marketing team
Biognosys is a leader in the proteomics space, providing cutting edge products and services to the global research community. As the business grew, so did the demand for high-quality content to increase brand awareness, generate leads, and drive sales. However, their...
Turning public opinions into compelling messaging
The Campaign for Science and Engineering (CaSE) believes that the UK should celebrate and invest in research and development (R&D). But without the public feeling the same way, R&D investment is unlikely to be a political priority. CaSE’s Discovery Decade...